A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults =65 Years of Age

Phase 1

Recruiting

• Conditions: Influenza virus; MedDRA version: 20.0Level: PTClassification code: 10022000Term: Influenza Class: 100000004862; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: CTIS2022-503004-24-00
• Lead Sponsor: Seqirus UK Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-11
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 35800

Inclusion Criteria

1. Adults of =65 years of age on the day of vaccination., 2. Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry., 3. Individuals who have the ability to comply with study procedures including follow-up.

Exclusion Criteria

1. Bedridden subjects (i.e. confined to bed by sickness or old age)., 10. Acute (severe) febrile illness., 11. Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study., 12. Study personnel or immediate family members (brother, sister, child, parent) or the spouse of study personnel., 13. Participation in the current study for more than one season., 2. Subjects that are incapacitated and because of that in need of a Legally Authorized Representative., 3. Receipt of any influenza vaccine within 6 months prior to enrollment or any plan to receive influenza vaccine while participating in the study., 4. Hypersensitivity, including allergy, to any component of vaccines whose use is foreseen in this study, or severe allergic reaction (e.g. anaphylaxis) to previous influenza vaccination., 5. Known history of Guillain-Barré syndrome or another demyelinating disease such as encephalomyelitis and transverse myelitis., 6. Clinical conditions representing a contra-indication to intramuscular administration of vaccines or blood draw., 7. Abnormal function of the immune system resulting from: a. Clinical conditions; b. Systemic administration of corticosteroids (PO/IV/IM)8 at a dose =20 mg/day of prednisone (or equivalent) for more than 14 consecutive days within 90 days prior to informed consent; Topical, inhaled and intranasal corticosteroids are permitted. Intermittent use (one dose in 30 days) of intra-articular corticosteroids are also permitted; c. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent;, 8. Receipt of immunoglobulins or any blood products within 180 days prior to informed consent;, 9. Receipt of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the study vaccination, or planned use during the entire study period.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified